AB 103

Drug Profile

AB 103

Alternative Names: AB-103; p 2 TA

Latest Information Update: 20 Jun 2016

Price : $50

At a glance

  • Originator Atox Bio
  • Class Antibacterials; Peptides
  • Mechanism of Action CD28 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Skin and soft tissue infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Skin and soft tissue infections
  • Phase I Sepsis

Most Recent Events

  • 15 Jun 2016 Atox Bio receives additional grant from US BARDA for the development of AB 103 for Necrotising soft tissue infections
  • 01 Sep 2015 Phase-III clinical trials in Skin and soft tissue infections in USA (IV) (NCT02469857)
  • 27 Jul 2015 Phase-II development is ongoing for Skin and soft tissue infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top